Authors

Sabrina McCrear

Latest:

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and payer access strategies.

Gillian McGovern

Gillian is an assistant editor for Pharmacy Times®.

Latest:

House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.

Rose McNulty is a Managing Editor for

Latest:

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

Jessica Mourani, PharmD

Jessica Mourani, PharmD, is Director of Clinical Outcomes for CPS Solutions.

Latest:

Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?

Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.

Lindsey Mulrooney

Latest:

Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections

Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Latest:

CVS Caremark Switches Up Biosimilar Coverage in 2024

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Kevin M. Nelson

Kevin M. Nelson is an intellectual property attorney

Latest:

IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal

Senior vice president, market solutions at Turquoise Health

Latest:

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.

Kathy Oubre, MS

Kathy W. Oubre, MS, is the Chief Operating Officer for Pontchartrain Cancer Center with locations in Covington and Hammond, Louisiana. In this role, she provides non-clinical leadership for all aspects of the practice, including financial counseling, policy/procedure development, revenue cycle management, advanced care planning, survivorship care and clinical trials.

Latest:

Biosimilars and Employers: Strategies for Success

The author, who is CEO of Pontchartrain Cancer Center, discusses how biosimilars can be part of a strategy for delivering high-quality care while achieving savings.

Sabina Alikhanov Palmieri, PharmD

Sabina Alikhanov Palmieri, PharmD, is a clinical pharmacy specialist with the Community Health Network of Connecticut.

Latest:

Updates on the Use of Biosimilars for Pediatric Patients With Rheumatic Disease

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

Advertisement

Advertisement